Sustainable synthesis of Hyaluronic Acid via engineered strains of non-pathogenic bacteria - from carbon dioxide and waste feedstock to low-cost, sustainable, and waste-free Hyaluronic Acid for cosmetics, medicine, and nutraceuticals

通过非致病性细菌的工程菌株可持续合成透明质酸 - 从二氧化碳和废弃原料到用于化妆品、药品和营养品的低成本、可持续且无废物的透明质酸

• 批准号: 10034038
• 金额: $ 50.97万
• 依托单位: 17CICADA LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10034038
• 关键词: Sustainable; synthesis; Hyaluronic; Acid; via

17Cicada anticipates market entry for its bacterial Hyaluronic Acid (HA) by 2025\. Our projected cumulative 5-year profits are of the order of £5.2 million (by 2029), i.e. 1033% return on investment (ROI) on project costs of £506,366 GBP.HA is widely distributed throughout connective, epithelial and neural tissues in human and animal bodies. It plays a significant range of biological roles, and is used in cosmetics (e.g. skin-moisturising and wrinkle-reducing products), cosmetic procedures (HA-based dermal fillers), medical treatment (e.g. eye surgery) and effective relief from osteoarthritis (by injecting HA into the joints).The global market for finished HA products was $20 billion in 2019 (Grand View Research), including $9b for medical products, $8b for cosmetics and $3 billion for nutraceutical products. Despite its chemical simplicity, HA-biochemistry is complex because it interacts differently with cell receptors depending on its molecular weight -- a property which paves the way for more technologically advanced medical products. The market anticipates a growth rate of 7.19% (CAGR) between Y2021-2028, driven mainly by an aging population and increasing aesthetic consciousness.Commercial HA is sourced from animals (rooster-comb) and competing, fermentation-based, non-animal products. The latter is based on bacterial cultures (especially _Streptococcus equi_) which are human pathogens. Although there is a powerful shift towards non-animal products, the use of human pathogens is problematic due to the immunogenic effect of protein/toxin residuals. This significant drawback can be greater in streptococcal-HA than in animal-sourced HA despite its low overall protein content. **It is therefore anticipated that microbial HA-production will shift towards non-pathogenic bacterial strains**.**Our vision** is a sustainable, bio-based HA which will spur medical innovation, reduce costs, abolish animal-sourced HA, and expand use of HA into stem cell therapy and tissue engineering. We envisage a revolution where small, digitally controlled HA bioreactors are operated by highly qualified personnel -- producing little or no waste, while consuming carbon and utilising less resource-intensive feedstocks.**Our key objectives** involve research on two engineered bacterial strains which are non-pathogenic, and which can consume either carbon dioxide or waste feedstocks. **We will focus** on producing HA in continuous production, coupled with robust techno-economic analyses to select the best strain for scale-up.**Our innovation** is a first-of-a-kind attempt to produce commercial HA via bacterial strains which are non-pathogenic _and_ which consume carbon dioxide and/or less resource-intensive feedstocks -- paving the way for novel nutraceuticals and lower-cost, more circular/sustainable HA-based cosmetic and medical products.

17Cicada 预计其细菌透明质酸 (HA) 将于 2025 年进入市场\。我们预计 5 年累计利润约为 520 万英镑（到 2029 年），即项目成本 1033% 的投资回报率 (ROI)。 506,366 GBP.HA广泛分布于人体和动物体内的结缔组织、上皮组织和神经组织中，发挥着重要的生物学作用。作用，并用于化妆品（例如皮肤保湿和除皱产品）、美容手术（基于透明质酸的真皮填充剂）、医疗（例如眼科手术）和有效缓解骨关节炎（通过将透明质酸注射到关节中）。 2019 年全球 HA 成品市场规模为 200 亿美元（Grand View Research），其中医疗产品 90 亿美元，化妆品 80 亿美元，化妆品 30 亿美元。尽管化学成分简单，但 HA 生物化学很复杂，因为它与细胞受体的相互作用不同，具体取决于其分子量，这一特性为技术更先进的医疗产品铺平了道路，市场预计增长率为 7.19%。 2021 年至 2028 年的复合年增长率），主要是由人口老龄化和审美意识增强推动的。商业 HA 来源于动物（鸡冠）和竞争性、基于发酵的、后者基于作为人类病原体的细菌培养物（尤其是马链球菌），尽管有向非动物产品的巨大转变，但由于蛋白质/毒素的免疫原性作用，人类病原体的使用存在问题。尽管链球菌-HA 的总蛋白质含量较低，但这种显着的波动可能比动物来源的 HA 更大。 **因此，预计微生物 HA 的生产将转向非致病菌。 **我们的愿景**是一种可持续的、生物基的透明质酸，它将刺激医疗创新、降低成本、废除动物来源的透明质酸，并将透明质酸的使用扩展到干细胞治疗和组织工程中。我们设想一场革命。其中小型、数字化控制的 HA 生物反应器由高素质人员操作，几乎不产生废物，同时消耗碳并利用资源密集型原料较少。 **我们的主要目标** 涉及对两种非工程细菌菌株的研究致病性，并且可以**我们将专注于**在连续生产中生产 HA，并结合强大的技术经济分析来选择最佳菌株进行放大。**我们的创新**是首创。 -通过非致病性且消耗二氧化碳和/或资源密集度较低的原料的细菌菌株生产商业HA的一种尝试——为新型营养保健品和更低成本、更循环/可持续的基于HA的产品铺平道路化妆品和医疗产品。